$386 Mln
$-155 Mln
--
As on 27-Sep-2023 16:00 EDT
$-0.02
•
-0.65%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bluebird bio Inc (BLUE)
| -55.78 | -11.82 | -5.56 | -40.70 | -56.40 | -49.17 | -15.63 |
|
S&P BSE Sensex*
| 7.67 | 0.96 | 3.30 | 14.71 | 20.56 | 12.52 | 12.75 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Bluebird bio Inc (BLUE)
| -30.73 | -64.34 | -50.69 | -11.54 | -44.12 | 188.65 | -3.92 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Bluebird bio Inc (BLUE) stood at $ 809 Mln as on 31-Mar-23
The share price of Bluebird bio Inc (BLUE) is $3.060000 (NASDAQ) as of 27-Sep-2023 16:00 EDT. Bluebird bio Inc (BLUE) has given a return of -56.4% in the last 3 years.
Bluebird bio Inc (BLUE) has a market capitalisation of $ 386 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Bluebird bio Inc (BLUE) is 4.37 times as on 02-Jun-2023, a 0.72% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Bluebird bio Inc (BLUE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bluebird bio Inc (BLUE) and enter the required number of quantities and click on buy to purchase the shares of Bluebird bio Inc (BLUE).
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
The CEO & director of Mr. Andrew Obenshain. is Bluebird bio Inc (BLUE), and CFO & Sr. VP is Mr. Thomas J. Klima.
The promoters of Bluebird bio Inc (BLUE) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
313
|
|
|
286
|
|
|
34
|
|
|
12
|
| Bluebird bio Inc (BLUE) | Ratios |
|---|---|
|
Return on equity(%)
|
-40.16
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Bluebird bio Inc (BLUE) was $-155 Mln.
$386.28 Mln
$4.03 Mln
$-155.42 Mln
$318.26 Mln
$273.38 Mln
High
$2.78 - 8.58
106,412,000
NASDAQ: BLUE
Cambridge, MA
https://www.bluebirdbio.com
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of... transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
